1. HBV/HDV Coinfection: A Challenge for Therapeutics.
- Author
-
Koh C, Da BL, and Glenn JS
- Subjects
- Antiviral Agents therapeutic use, Clinical Trials, Phase III as Topic, Drugs, Investigational pharmacology, Drugs, Investigational therapeutic use, Female, Hepatitis B virus isolation & purification, Hepatitis B, Chronic diagnosis, Hepatitis B, Chronic drug therapy, Hepatitis B, Chronic epidemiology, Hepatitis D, Chronic diagnosis, Hepatitis D, Chronic epidemiology, Humans, Male, Piperidines therapeutic use, Prognosis, Pyridines therapeutic use, Recombinant Proteins therapeutic use, Risk Assessment, Treatment Outcome, Coinfection drug therapy, Hepatitis B virus drug effects, Hepatitis D, Chronic drug therapy, Hepatitis Delta Virus drug effects, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use
- Abstract
Chronic hepatitis D (CHD) results from an infection with the hepatitis B virus and hepatitis D virus (HDV). CHD is the most severe form of human viral hepatitis. Current treatment options consist of interferon alfa, which is effective only in a minority of patients. Study of HDV molecular virology has resulted in new approaches entering clinical trials, with phase-3 studies the most advanced. These include the entry inhibitor bulevirtide, the nucleic acid polymer REP 2139-Ca, the farnesyltransferase inhibitor lonafarnib, and pegylated interferon lambda. This article summarizes the available data on these emerging therapeutics., (Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF